ReviewInternational journal of molecular sciences2022
Human Lung Mast Cells: Therapeutic Implications in Asthma.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Vascular remodeling in asthma: from mechanisms to precision medicine.Current opinion in allergy and clinical immunology · 2026Review
- Mast cells support lung eosinophil homeostasis and the acute innate immune response to respiratory syncytial virus.Nature communications · 2026Article
- Leveraging ADMET Profiling, Network Pharmacology, and Molecular Docking to Evaluate the Repurposing of Product Nkabinde for COVID-19 Treatment.Biomedicines · 2026Article
- Article
- Calcitonin gene-related peptide promotes mast cell-mediated neuroimmune inflammation through the CALCRL/RAMP1-JAK3-STAT1 axis in rosacea.Frontiers in immunology · 2026Article
- Mast cells promote pathology and susceptibility in tuberculosis.bioRxiv : the preprint server for biology · 2025Article
- Histamine as a mediator of cross-talk between human lung mast cells and macrophages.Scientific reports · 2025Article
- The Junction of Allergic Inflammation and Atherosclerosis: Pathways and Clinical Implications-A Review.Life (Basel, Switzerland) · 2025Review
- Transfusion-Related Acute Lung Injury: from Mechanistic Insights to Therapeutic Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Immunomodulatory Significance of Mast Cell Exosomes (MC-EXOs) in Immune Response Coordination.Clinical reviews in allergy & immunology · 2025Review
- Mucus and mucin: changes in the mucus barrier in disease states.Tissue barriers · 2025Review
- T cell heterogeneity in asthma pathogenesis: from immunological mechanisms to biological targeted therapies.Frontiers in immunology · 2025Review
- A Review on Asthma and Allergy: Current Understanding on Molecular Perspectives.Journal of clinical medicine · 2024Review
- Mast cells: a novel therapeutic avenue for cardiovascular diseases?Cardiovascular research · 2024Review
- Thymic Stromal Lymphopoietin (TSLP) Is Cleaved by Human Mast Cell Tryptase and Chymase.International journal of molecular sciences · 2024Article
- Airway remodelling in asthma and the epithelium: on the edge of a new era.The European respiratory journal · 2024Review
- The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.The European respiratory journal · 2024Review
- The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells.Frontiers in immunology · 2024Article
- Mast Cells and Basophils in IgE-Independent Anaphylaxis.International journal of molecular sciences · 2023Review
- Mast Cells in Upper and Lower Airway Diseases: Sentinels in the Front Line.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Mast cells are strategically located in different compartments of the lung in asthmatic patients. These cells are widely recognized as central effectors and immunomodulators in different asthma phenotypes. Mast cell mediators activate a wide spectrum of cells of the innate and adaptive immune system during airway inflammation. Moreover, these cells modulate the activities of several structural cells (i.e., fibroblasts, airway smooth muscle cells, bronchial epithelial and goblet cells, and endothelial cells) in the human lung. These findings indicate that lung mast cells and their mediators significantly contribute to the immune induction of airway remodeling in severe asthma. Therapies targeting mast cell mediators and/or their receptors, including monoclonal antibodies targeting IgE, IL-4/IL-13, IL-5/IL-5Rα, IL-4Rα, TSLP, and IL-33, have been found safe and effective in the treatment of different phenotypes of asthma. Moreover, agonists of inhibitory receptors expressed by human mast cells (Siglec-8, Siglec-6) are under investigation for asthma treatment. Increasing evidence suggests that different approaches to depleting mast cells show promising results in severe asthma treatment. Novel treatments targeting mast cells can presumably change the course of the disease and induce drug-free remission in bronchial asthma. Here, we provide an overview of current and promising treatments for asthma that directly or indirectly target lung mast cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.